Search results
Supernus Pharmaceuticals, Inc.'s (NASDAQ:SUPN) Stock Is Rallying But Financials Look Ambiguous: Will...
Simply Wall St. via Yahoo Finance· 2 years agoSupernus Pharmaceuticals (NASDAQ:SUPN) has had a great run on the share market with its stock up by...
Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Has Fared Decently But Fundamentals Look Uncertain:...
Simply Wall St. via Yahoo Finance· 4 months agoMost readers would already know that Supernus Pharmaceuticals' (NASDAQ:SUPN) stock increased by 9.4%...
Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Q3 2022 Earnings Call Transcript
Insider Monkey via Yahoo Finance· 1 year agoSupernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Q3 2022 Earnings Call Transcript November 8, 2022...
Supernus Pharmaceuticals Inc (SUPN) Reports Robust Growth in Key Products for Full Year 2023
GuruFocus.com via Yahoo Finance· 3 months agoNet Sales Growth: Qelbree's net sales surged by 129% to $140.2 million in 2023, while GOCOVRI...
Insider Sell Alert: Director Frederick Hudson Sells 9,093 Shares of Supernus Pharmaceuticals ...
GuruFocus.com via Yahoo Finance· 6 months agoSupernus Pharmaceuticals Inc (NASDAQ:SUPN), a biopharmaceutical company focused on developing and...
Supernus Pharmaceuticals (SUPN): A Hidden Gem in the Market? A Comprehensive Analysis of Its ...
GuruFocus.com via Yahoo Finance· 8 months agoSupernus Pharmaceuticals Inc (NASDAQ:SUPN) has recently seen a daily gain of 2.28%, despite a...
Do Options Traders Know Something About Supernus (SUPN) Stock We Don't?
Zacks via Yahoo Finance· 2 days agoInvestors in Supernus Pharmaceuticals, Inc. SUPN need to pay close attention to the stock based on...
Supernus Pharmaceuticals Faces Second FDA Rejection For Investigational Device For Parkinson's...
Benzinga via Yahoo Finance· 2 months agoOn Monday, Supernus Pharmaceuticals Inc. (NASDAQ:SUPN) announced a regulatory update for SPN-830, an...
Q4 2023 Supernus Pharmaceuticals Inc Earnings Call
Thomson Reuters StreetEvents via Yahoo Finance· 3 months agoParticipants Jack Khattar; President, Chief Executive Officer, Secretary, Director; Supernus Pharmaceuticals Inc Timothy Dec; Chief Financial Officer, Senior Vice President; Supernus Pharmaceuticals ...
Supernus Pharmaceuticals (NASDAQ:SUPN) shareholders have earned a 8.7% CAGR over the last three...
Simply Wall St. via Yahoo Finance· 6 months agoIt hasn't been the best quarter for Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) shareholders, since...
